1 / 39

Thyroid and energy expenditure

Thyroid and energy expenditure. Francesco S. Celi, M.D. Staff Clinician Clinical Endocrinology Branch. Overview. The thyroid hormone action as a modulator of the energy and substrate metabolism homeostasis Tissue-specific thyroid hormone metabolism

ilar
Download Presentation

Thyroid and energy expenditure

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Thyroid and energy expenditure Francesco S. Celi, M.D. Staff Clinician Clinical Endocrinology Branch

  2. Overview • The thyroid hormone action as a modulator of the energy and substrate metabolism homeostasis • Tissue-specific thyroid hormone metabolism • Recent clinical studies on the interaction between thyroid hormone homeostasis and glucose and energy metabolism • Technical challenges in the assessment of the metabolic status of healthy individuals • Ongoing studies on the role of thyroid hormones conversion in the energy and substrate metabolism • Preliminary results • Future perspectives

  3. A few (unresolved) questions… • Why is the clinical presentation of thyroid diseases so variable? • Where does (circulating) T3 come from? • What is the action of thyroid hormone on glucose metabolism? • What makes the thyroid hormone actions tissue-specific? • Can we exploit the action of thyroid hormone? (without paying the price)

  4. I I R I The researcher’s view of the universe“The thyroid hormone action is controlled by a redundant, multilevel highly regulated mechanism” Hypothalamus Pituitary Thyroid Plasma transport Cellular transport Local conversion RX RXR TR Receptors/Co-activators

  5. The researcher’s view of the universe Local conversion

  6. 3’ 3 I I HO O R 5’ 5 I I 3’ 3 3’ 3 I I I HO O R HO O R 5’ 5 5’ 5 I I The Deiodinases : Activation and Inactivation of Thyroid Hormones T4 D 1, D 2 D 3, ( D 1) I T3 rT3

  7. The role of the Selenocysteine Insertion Sequence (SECIS) in the incorporation of the selenocysteine NH2 AAAAAAAAA SECIS Element SeCys A A A 30 S UGA UAA 5’ STOP (STOP) mRNA 50 S

  8. Type 1 Type 2 Type 3 Site of action 5’ 5 5’ and 5 Substrate rT3>T4>T3 T4>T3 T3>T4 Localization Kidney, liver, thyroid placenta, CNS Pituitary, CNS, muscle, BAT, thyroid, placenta Hypothyroidism Inhibition Stimulation Inhibition Hyperthyroidism Stimulation Inhibition Stimulation Km (T4) 2 mM 2 nM 37 nM Deiodinases: types and characteristics

  9. The peripheral metabolism of thyroid hormone in the local modulation thyroid homeostasis • The peripheral conversion of thyroid hormone and the pre-receptor modulation of the hormonal message • Aromatase • 11b-hydroxysteroid dehydrogenase • 5a-reductase • The deiodinase type-2 as a candidate gene for tissue-specific hypothyroidism

  10. Type 2 deiodinaselocal pre-receptor modulation of hormonal action • Differentially expressed in many tissues • Provides T3 for local use (autocrine secretion) • Possible role in the regulation of circulating T3 • Critical step in pituitary for thyroid axis feedback • Critical step in non-shivering thermogenesis • Highly regulated • Transcription • Post-transcription • Post-translation

  11. Clinical relevance of deiodinases • Type 1 • Euthyroid sick syndrome • Effects of pharmacological intervention • Graves’, Toxic nodule, MAS • Type 2 • Pituitary thyroid hormone resistance • Graves’, Toxic nodule, MAS • Euthyroid sick syndrome • Type 3 • Protection of fetus from toxic levels of thyroid hormone • Euthyroid sick syndrome • “Paraneoplastic hypothyroidism”

  12. The Deiodinases and the Euthyroid Sick Syndrome “Changes in circulating thyroid hormones secondary to underlying illness in the absence of primary thyroid pathology” Low T3: Deiodinase type-1 inhibition, easy! …Not exactly… Why is the rT3 elevated? Why is the TSH inappropriately low? And if we assume an accumulation of substrate, why is the T4 low?

  13. D2 T4 T4 T3 rT3 The deiodinases in the pathogenesis of euthyroid sick syndrome Hypothalamus Inflammatory mediators TRH • low T3 • low T4 • low TSH • high rT3 Pituitary Liver TSH T4 T4 T3 D1 Hypoxia D3 rT3 T2 Ectopic D3 activity

  14. The role of the deiodinases in the pathophysiology of the euthyroid sick syndrome • Type 1: decreased transcription due to recruitment of co-activators by the inflammatory cytokines, further decrease by the lack of T3 • Decrease in T3, increase in rT3 • Type 2: increased activity in the glial cells feeding the hypothalamus TRH neurons, ultimately inhibiting the TRH-TSH axis • Decrease in TSH, inhibition of thyroid activity • Type 3: increased transcription and activity due to hypoxia • Increase in rT3, decrease in T4

  15. Thyrotoxicosis Increased energy expenditure Increased lipid oxidation Weight loss The action of thyroid hormone on glucose and energy metabolismLessons from patients Energy Metabolism • Hypothyroidism • Decreased energy expenditure • Increased sympathetic tone • Weight gain?

  16. The action of thyroid hormone on glucose and energy metabolismLessons from patients Glucose Metabolism • Thyrotoxicosis • Increased hepatic gluconeogenesis • Decreased insulin half-life • Muscle mass loss • Increased glucose disposal • Hypothyroidism • Decreased hepatic gluconeogenesis • Increased insulin half-life • Decreased glucose disposal

  17. The action of thyroid hormone on glucose and energy metabolismEpidemiological studies The association between TSH within the reference range and serum lipid concentrations in a population-based study. The HUNT Study. Asvold et al, Eur J Endocrinol. 2007 Feb;156(2):181-6. Plasma concentrations of free triiodothyronine predict weight change in euthyroid persons. Ortega et al, Am J Clin Nutr. 2007 Feb;85(2):440-5. Free triiodothyronine plasma concentrations are positively associated with insulin secretion in euthyroid individuals. Ortega et al, Eur J Endocrinol. 2008 Feb;158(2):217-21.

  18. The action of thyroid hormone on glucose and energy metabolismMolecular genetics studies Association between a novel variant of the human type 2 deiodinase gene Thr92Ala and insulin resistance: evidence of interaction with the Trp64Arg variant of the beta-3-adrenergic receptor Mentuccia et al, Diabetes. 2002 Mar;51(3):880-3 The type 2 deiodinase A/G (Thr92Ala) polymorphism is associated with decreased enzyme velocity and increased insulin resistance in patients with type 2 diabetes mellitus Canani et al, J Clin Endocrinol Metab. 2005 Jun;90(6):3472-8. The type 2 deiodinase (DIO2) A/G polymorphism is not associated with glycemic traits: the Framingham Heart Study. Maia et al, Thyroid. 2007 Mar;17(3):199-202. The Asp727Glu polymorphism in the TSH receptor is associated with insulin resistance in healthy elderly men Peeters et al, Clin Endocrinol. 2007 Jun;66(6):808-15.

  19. Thyroid disease in the geriatric populationwhat is normal? • Prevalent condition (if assessed by TSH alone) • Very aspecific symptoms/signs (Douchet J Am Geriatr Soc. 1994 Sep;42(9):984-6). • Predominant symptoms: fatigue and weakness • Paradoxicaly associated (hypothyroidism) with increased survival (Singer RB J Insur Med. 2006;38(1):14-9. Gussekloo J. et al. JAMA. 2004 Dec 1;292(21):2591-9)

  20. Technical challenges in the assessment of the metabolic status of healthy individualsas related to thyroid homeostasis • Inter-individual variability of thyroid homeostasis parameters • Inter-individual variability of clinical expression of thyroid homeostasis as it relates to circulating thyroid hormones • Role of thyroid hormone action as modulator of metabolic status

  21. Technical challenges in the assessment of the metabolic status of healthy individuals • Inter-individual variability of metabolic parameters • Intra-individual variability of metabolic parameters (nutritional/activity/environmental) • Relative poor performance of the assessment tools (good accuracy, poor precision)

  22. Technical challenges in the assessment of the metabolic status of healthy individualsstudy design • Careful selection of study participants • Specific conditions (e.g. RTH, MAS) • Healthy volunteers • Specific genotypes • Accurate evaluation of baseline conditions • Use of Clinical Research Centers • Use of study designs aimed to improve the accuracy of the results • Cross-over • Sib-pair

  23. Clinical Studies-ongoing • 05-DK-0119: Peripheral Thyroid Hormone Conversion and Glucose and Energy Metabolism • 06-DK-0133: Thyroid Hormone-Induced Lipolysis: An In Vivo Microdialysis Study • 07-DK-0202: Thyroid hormones homeostasis and energy metabolism changes during exposure to cold temperature in humans • 06-DK-0183: Gene Expression and Release of Inflammatory Mediators in Overweight Subjects Before and After Weight Loss

  24. 05-DK-0119 Peripheral Thyroid Hormone Conversion and Glucose and Energy Metabolism Study Objectives Background • Levothyroxine replacement therapy might not be effective in assuring the thyroid homeostasis in all target organs/systems. Study Aims: • To assess the differential pituitary response to escalating dose TRH stimulation test. • To assess the changes in glucose metabolism by euglycemic hyperinsulinemic clamp. • To analyze the changes in lipid metabolism by assessing the changes in cholesterol, triglycerides and apolipoproteins • To assess the changes in cardiovascular function by echocardiogram, vascular endothelial function and EKG, both resting and post exercise.

  25. Inclusion Criteria Total/near total thyroidectomy Remnant volume < 1 mL LT4 dose ≥ 1.6 mg/kg Primary Hypothyroidism LT4 dose ≥ 1.6 mg/kg 24-hour uptake < 5% Exclusion Criteria Suppressive therapy BMI ≤20 or ≥30 kg/m2 Cardiovascular disease Diabetes Mellitus Hypercholesterolemia Subject Selection Criteria

  26. Therapy adjustment Therapy adjustment Therapy adjustment Therapy adjustment Metabolic testing Metabolic testing T3 therapy Randomization Enrollment T4 therapy Metabolic testing Metabolic testing Therapy adjustment Therapy adjustment Therapy adjustment Therapy adjustment 05-DK-0119 Study design Therapy adjustment intervals: 10 days; TSH goal > 0.5 < 1.5 mcIU/mL

  27. 05-DK-0119 Preliminary data • 7 study subjects (6 F, 1 M) age 49.6  4.3 years, BMI 25.8  3.1 kg/m2. • T3 vs. T4 TSH at admission (0.51  0.16 vs. 0.62  0.46 mU/L p=0.59). • T3 dose 41.4  12.3 mcg (0.6  0.1 mcg/kg) • T4 dose 123.2  37.2 mcg (1.7  0.3 mcg/kg) • T3:T4 ratio 0.34  0.05 • Time-to-target on T4 202  81 days • Time-to-target on T3 167  87 days

  28. * *      ■ ■  Liothyronine vs. Levothyroxine Dose 200 90 LT3 dose 41.4  12.3 mcg (0.6  0.1 mcg/kg) LT4 dose 123.2  37.2 mcg (1.7  0.3 mcg/kg) 150 60 100 30 LT3:LT4 ratio 0.34 0.05 mcg/mcg

  29. 05-DK-0119 Preliminary data • Free T4 levels at admission • T3 therapy < 0.3 ng/dL • T4 Therapy 1.610.37 ng/dL Reference values 0.8-1.9 ng/dL

  30. 05-DK-0119 Preliminary data • Total T3 levels at admission • T3 therapy 167.7169.17ng/dL • T4 Therapy 87.5724.08 ng/dL Reference values 90-215 ng/dL

  31. 24-Hour Serum Total T3 Profile T3 ng/dL Reference values 90-215 ng/dL

  32. 24-Hour Serum TSH Profile TSH mcu/mL Reference values 0.5-4.0 mcU/mL

  33. 05-DK-0119 Preliminary data • AUC 0-60 after 200 mcg TRH • T3 281.4113.6 mU*min /L • T4 282.5165.6 mU*min /L • First steady-state pharmaco bioequivalency data on T3 vs. T4. • Proof of concept of effective substitution of T3 for T4 therapy. • Tool to study in vivo the physiological role of deiodination.

  34. 07-DK-0202 Thyroid hormones homeostasis and energy metabolism changes during exposure to cold temperature in humansBackground/study aims Changes in environmental temperature generate a substantial differential in energy expenditure and substrate utilization (in animal models) It is not clear whether changes within the thermo-neutral zone result in measurable and clinically relevant changes in these parameters To assess the effects of environmental temperature changes on energy expenditure, substrate utilization and thyroid hormone homeostasis parameters in healthy volunteers

  35. 07-DK-0202 Thyroid hormones homeostasis and energy metabolism changes during exposure to cold temperature in humansStudy Design • Two-day equilibration diet • Randomization to either 19C or 24C • 12-hour metabolic chamber stay • Energy expenditure/RQ • Frequent samples levels thyroid hormones, cathecolamines, free fatty acids • Core temperature • Lipolysis rate (by microdialysis) • Thermic effect of food • 36-hour resting period • Cross over to second temperature

  36. 07-DK-0202 Study protocol, overview 19 C 12-hour metabolic chamber 12-hour metabolic chamber Equilibration diet Equilibration diet Metabolic Unit admission Enrollment 24 C Equilibration diet Equilibration diet 12-hour metabolic chamber 12-hour metabolic chamber Equilibration diet: 2 days

  37. Conclusions • Several epidemiological studies indicate that in healthy individuals the thyroid homeostasis plays a modulator role in the carbohydrate, lipid and energy metabolism. • The overall effects of thyroid hormone action in healthy individuals on metabolic control is small and within the variance of the general population • These factors should be taken in consideration in the design of intervention/association studies

  38. Acknowledgments • Monica Skarulis • Joyce Linderman • Valentina Congedo • Marina Zemskova • Nabeel Babar • Christopher Harris • Merel Kozlosky • Blakeley Denkinger • Nancy Sebring • Kong Chen • Robert Brychta • Megan Rothney • Emily Schaefer • Frank Pucino • Gyorgy Csako • Alan Remaley • Louis Simchowitz • Marvin Gershengorn Nurses and Personnel of 5 SW-Metabolic Unit

  39. Acknowledgments • Study Volunteers • Nursing and Clinic Personnel • Pharmacy Department • Department of Laboratory Medicine This study was supported by the Intramural Research Program of the NIDDK-NIH Jacob Robbins 1923-2008

More Related